open access

Vol 5, No 6 (2016)
Pharmaceutical news
Published online: 2017-03-31
Get Citation

Clinical value of glargine 300 U/mL based on randomized trials and routine medical practice

Leszek Czupryniak, Grzegorz Dzida, Janusz Gumprecht, Przemysława Jarosz-Chobot, Tomasz Klupa, Malgorzata Szelachowska, Bogumił Wolnik, Albert Syta
DOI: 10.5603/DK.2016.0035
·
Clinical Diabetology 2016;5(6):203-207.

open access

Vol 5, No 6 (2016)
Pharmaceutical news
Published online: 2017-03-31

Abstract

The paper presents available evidence on the clinical use of glargine 300 IU/mL, the latest addition to the diabetes care armamentarium.

Abstract

The paper presents available evidence on the clinical use of glargine 300 IU/mL, the latest addition to the diabetes care armamentarium.

Get Citation

Keywords

glargine, type 2 diabetes, insulin therapy

About this article
Title

Clinical value of glargine 300 U/mL based on randomized trials and routine medical practice

Journal

Clinical Diabetology

Issue

Vol 5, No 6 (2016)

Pages

203-207

Published online

2017-03-31

DOI

10.5603/DK.2016.0035

Bibliographic record

Clinical Diabetology 2016;5(6):203-207.

Keywords

glargine
type 2 diabetes
insulin therapy

Authors

Leszek Czupryniak
Grzegorz Dzida
Janusz Gumprecht
Przemysława Jarosz-Chobot
Tomasz Klupa
Malgorzata Szelachowska
Bogumił Wolnik
Albert Syta

References (28)
  1. Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016; 32(6): 478–496.
  2. Sutton G, Minguet J, Ferrero C, et al. U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014; 14(12): 1849–1860.
  3. Summary of Product Characteristics Toujeo. www.ema.europa.eu (07.02.2017).
  4. Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015; 17(3): 254–260.
  5. Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000; 50(3): 161–167.
  6. Becker RHA, Dahmen R, Bergmann K, et al. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1. Diabetes Care. 2015; 38(4): 637–643.
  7. Becker RHA, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015; 17(3): 261–267.
  8. Satya Krishna SV, Kota SK, Modi KD. Glycemic variability: Clinical implications. Indian J Endocrinol Metab. 2013; 17(4): 611–619.
  9. Saisho Y. Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? Int J Mol Sci. 2014; 15(10): 18381–18406.
  10. Torimoto K, Okada Y, Mori H, et al. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013; 12: 1.
  11. Riddle MC, Bolli GB, Ziemen M, et al. EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014; 37(10): 2755–2762.
  12. Yki-Järvinen H, Bergenstal R, Ziemen M, et al. EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014; 37(12): 3235–3243.
  13. Bolli GB, Riddle MC, Bergenstal RM, et al. on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015; 17(4): 386–394.
  14. Home PD, Bergenstal RM, Bolli GB, et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care. 2015; 38(12): 2217–2225.
  15. Ritzel R, Roussel R, Giaccari A et al. glycemic control and hypoglycemia with insulin glargine 300 U/mL (Gla300) vs. glargine 100 U/mL (Gla100) in type 2 diabetes (T2DM) in a patient level metaanalysis of 1Yr phase 3a EDITION studies. Poster presentation at ADA. http://app.core-apps.com/tristar-ada15/abstracts. (5-9.06.2015).
  16. Tong L, Wang H, Gupta S et al. Effect of switching to insulin glargine 300 U/mL on clinical outcomes in patients with type 2 diabetes: a medical chart-review study in the US. Poster presentation at 14th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC);. http://www.kantarhealth.com/clinical-publications (1-3.12.2016).
  17. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Diabetologia Kliniczna. 2016; 5(Suppl A).
  18. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6): 1364–1379.
  19. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008; 51(3): 408–416.
  20. Hollander P, Cooper J, Bregnhøj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008; 30(11): 1976–1987.
  21. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010; 33(6): 1176–1178.
  22. Jakobsen M, Dalsgaard M, Hørmann M, et al. Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. BMC Endocr Disord. 2012; 12: 21.
  23. McAdam-Marx C, Yu J, Bouchard J, et al. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin. 2010; 26(1): 191–201.
  24. Feinkohl I, Aung PP, Keller M, et al. Edinburgh Type 2 Diabetes Study (ET2DS) Investigators. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014; 37(2): 507–515.
  25. Brod M, Wolden M, Christensen T, et al. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab. 2013; 15(6): 546–557.
  26. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013; 36: 138.
  27. Jeandidier N, Riddle MC, Bolli GB et al. New insulin glargine 300 U/mL: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus. Poster presentation at EASD 2014, . http://www.easdvirtualmeeting.org/resources/18792 (07.02.2017).
  28. Wang H, Zhang Q, Frois C et al. Safety and Efficacy of Insulin Glargine 300 U/mL (Gla-300) compared with other basal insulin therapies in patients with type 2 diabetes mellitus (T2DM) — A Network Meta-analysis (NMA). Oral presentation at ADA, 5–9 June 2015, Boston, MA, USA. http://app.core-apps.com/tristarada15/abstracts.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl